RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the ...

The CDC's newly rebuilt Advisory Committee on Immunization Practices (ACIP) took aim Thursday at a mercury-based preservative ...

"The severity of this past flu season underscores the need for more effective vaccines." Moderna cited data from the Centers for Disease Control and Prevention showing that seasonal flu-related ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The CDC's Advisory Committee on Immunization Practices recommended the removal of the preservative thimerosal in seasonal influenza vaccines at their meeting.

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

The vaccine panel hand-selected by health secretary and anti-vaccine advocate Robert F. Kennedy Jr. on Thursday voted ...

When the seasonal flu strikes, most people expect the familiar lineup of fever, aches and congestion. But for many patients, dizziness emerges as an ...

While respiratory illnesses such as flu and cough affect Ugandans year-round, researchers have identified specific months ...